BRINTELLIX
Drug
H. Lundbeck A S
Total Payments
$7.0M
Transactions
33,561
Doctors
8,158
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $657,506 | 697 | 282 |
| 2023 | $1.8M | 1,738 | 707 |
| 2022 | $907,832 | 2,574 | 1,031 |
| 2021 | $700,394 | 12,514 | 4,585 |
| 2020 | $752,715 | 5,651 | 2,212 |
| 2019 | $2.2M | 10,387 | 3,109 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.9M | 1,292 | 85.2% |
| Food and Beverage | $510,322 | 32,067 | 7.3% |
| Honoraria | $335,820 | 82 | 4.8% |
| Travel and Lodging | $183,616 | 56 | 2.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,158 | 3 | 0.0% |
| Education | $261.33 | 61 | 0.0% |
Payments by Type
Research
$5.9M
1,292 transactions
General
$1.0M
32,269 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | H. Lundbeck A S | $2.9M | 0 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder MDD | H. Lundbeck A S | $731,225 | 0 |
| Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD | H. Lundbeck A S | $707,048 | 0 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD) | H. Lundbeck A S | $480,381 | 0 |
| Real-life Effectiveness of Vortioxetine in Depression RELIEVE | H. Lundbeck A S | $295,484 | 2 |
| ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS AGED 7 TO 11 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) | H. Lundbeck A S | $293,280 | 0 |
| VORTIOXETINE TO PREVENT RETURN OF SYMPTOMS IN CHILDREN WITH DEPRESSION | H. Lundbeck A S | $180,443 | 0 |
| Real-life Effectiveness of Vortioxetine in Depression (RELIEVE) | H. Lundbeck A S | $106,343 | 1 |
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age | H. Lundbeck A S | $86,368 | 0 |
| REAL-LIFE EFFECTIVENESS OF VORTIOXETINE IN DEPRESSION (RELIEVE) | H. Lundbeck A S | $73,787 | 0 |
| 17354N | H. Lundbeck A S | $35,861 | 0 |
| LONG-TERM, OPEN-LABEL, FLEXIBLE-DOSE, EXTENSION STUDY OF VORTIOXETINE IN CHILD AND ADOLESCENT PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) FROM 7 TO 18 YEARS OF AGE | H. Lundbeck A S | $27,946 | 0 |
| AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) | H. Lundbeck A S | $18,800 | 0 |
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age | H. Lundbeck A S | $18,604 | 0 |
| Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD) | H. Lundbeck A S | $7,144 | 0 |
| Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder GAD RECONNECT | H. Lundbeck A S | $2,000 | 1 |
| Vortioxetine in Patients With Depression and Early Dementia MEMORY | H. Lundbeck A S | $2,000 | 1 |
| ACTIVE REFERENCE (FLUOXETINE) FIXED-DOSE STUDY OF VORTIOXETINE IN PAEDIATRIC PATIENTS AGED 12 TO 17 YEARS WITH MAJOR DEPRESSIVE DISORDER (MDD) | H. Lundbeck A S | $500.00 | 0 |
Top Doctors Receiving Payments for BRINTELLIX
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Tejas Patel | — | Scottsdale, AZ | $5.9M | 1,285 |
| , M.D | Psychiatry | Saint Charles, MO | $207,888 | 55 |
| , MD | Psychiatry | University Park, FL | $40,460 | 9 |
| , M.D | Child & Adolescent Psychiatry | New York, NY | $37,710 | 13 |
| , MD | Specialist | Carlsbad, CA | $36,939 | 10 |
| Vladimir Maletic | — | Greer, SC | $29,330 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | East Setauket, NY | $26,250 | 14 |
| , MD | Psychiatry | Glen Oaks, NY | $21,023 | 7 |
| , M.D | Neurology | Kansas City, KS | $19,519 | 6 |
| , MD | Neurology | Rochester, NY | $17,041 | 4 |
| , M.D | Psychiatry | Coral Gables, FL | $16,449 | 22 |
| , MD | Psychiatry | Boston, MA | $13,506 | 6 |
| , MD | Psychiatry | Fort Wayne, IN | $12,605 | 15 |
| , MD | Clinical Neurophysiology | Washington, DC | $9,600 | 2 |
| , MD | Neuromuscular Medicine | Philadelphia, PA | $8,291 | 4 |
| , M.D | Psychiatry | Costa Mesa, CA | $7,803 | 15 |
| Karam Radwan | Psychiatry | Chicago, IL | $5,589 | 4 |
| , MD | Psychiatry | Jacksonville, FL | $5,315 | 4 |
| , MD | Psychiatry | Rochester Hills, MI | $4,295 | 23 |
| , M.D | Psychiatry | New York, NY | $4,000 | 1 |
| , MD | Psychiatry | Tampa, FL | $4,000 | 2 |
| , M.D | Psychiatry | Boca Raton, FL | $3,500 | 1 |
| , MD | Geriatric Psychiatry | Saint Louis, MO | $3,453 | 4 |
| , MD | Psychiatry | Philadelphia, PA | $3,375 | 1 |
| , MD | Psychiatry | Grand Rapids, MI | $3,010 | 1 |
Ad
Manufacturing Companies
- H. Lundbeck A S $6.5M
- Lundbeck LLC $507,854
Product Information
- Type Drug
- Total Payments $7.0M
- Total Doctors 8,158
- Transactions 33,561
About BRINTELLIX
BRINTELLIX is a drug associated with $7.0M in payments to 8,158 healthcare providers, recorded across 33,561 transactions in the CMS Open Payments database. The primary manufacturer is H. Lundbeck A S.
Payment data is available from 2019 to 2024. In 2024, $657,506 was paid across 697 transactions to 282 doctors.
The most common payment nature for BRINTELLIX is "Unspecified" ($5.9M, 85.2% of total).
BRINTELLIX is associated with 18 research studies, including "AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED)" ($2.9M).